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Background: It has been reported that increased expression of UCP-2 in the vasculature may prevent the development
of atherosclerosis in patients with increased production of reactive oxygen species, as in the diabetes, obesity
or hypertension. Thus, a greater understanding in the modulation of UCP-2 could improve the atherosclerotic
process. However, the effect of TNF-α or insulin modulating UCP-2 in the vascular wall is completely unknown. In this
context, we propose to study new molecular mechanisms that help to explain whether the moderate hyperinsulinemia
or lowering TNF-α levels might have a protective role against vascular damage mediated by UCP-2 expression levels.
Methods: We analyzed the effect of insulin or oleic acid in presence or not of TNF-α on UCP-2 expression in murine
endothelial and vascular smooth muscle cells. At this step, we wondered if some mechanisms studied in vitro could be
of any relevance in vivo. We used the following experimental models: ApoE−/− mice under Western type diet for 2,
6, 12 or 18 weeks, BATIRKO mice under high-fat diet for 16 weeks and 52-week-old BATIRKO mice with o without
anti-TNF-α antibody pre-treatment.
Results: Firstly, we found that TNF-α pre-treatment reduced UCP-2 expression induced by insulin in vascular cells.
Secondly, we observed a progressive reduction of UCP-2 levels together with an increase of lipid depots and lesion
area in aorta from ApoE−/− mice. In vivo, we also observed that moderate hyperinsulinemic obese BATIRKO mice have
lower TNF-α and ROS levels and increased UCP-2 expression levels within the aorta, lower lipid accumulation, vascular
dysfunction and macrovascular damage. We also observed that the anti-TNF-α antibody pre-treatment impaired the
loss of UCP-2 expression within the aorta and relieved vascular damage observed in 52-week-old BATIRKO mice. Finally,
we observed that the pretreatment with iNOS inhibitor prevented UCP-2 reduction induced by TNF-α in vascular cells.
Moreover, iNOS levels are augmented in aorta from mice with lower UCP-2 levels and higher TNF-α levels.
Conclusions: Our data suggest that moderate hyperinsulinemia in response to insulin resistance or lowering of TNF-α
levels within the aorta attenuates vascular damage, this protective effect being mediated by UCP-2 expression levels
through iNOS.
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Uncoupling proteins (UCPs) belong to the family of
mitochondrial transporter proteins and are important
for lowering mitochondrial membrane potential and
dissipating metabolic energy as heat, maintenance of
respiration, glucose disposal rate, insulin secretion,
prevention of reactive oxygen species (ROS) production
[1,2]. UCP-1 was the first member identified, expressed
primarily in brown adipose tissue and the major
contributor to energy expenditure [3]. Other four
members of UCP (−2 to −5) family have been indentified.
In contrast to UCP-4 and −5, human UCP-2 and −3 are
both more closely related to UCP-1 [4,5]. UCP-2 is
expressed widely and in human is highly expressed in
white adipose tissue. Other tissues as skeletal muscle,
heart, cell of immune system and vascular cells express
considerable amounts of UCP-2 [6]. Recent studies from
UCP-2 and −3 knockout mice suggest that both UCPs
have uncoupling activity and decreased ROS production
in macrophages and skeletal muscle, respectively [7–9].
More recently, a direct role for UCP-2 in the regulation of
atherogenesis has been suggested by the observation that
bone marrow transplantation from UCP-2-deficient mice
to LDLR−/− mice markedly increased atherosclerotic
lesion size [10]. Moreover, it has been described that
UCP-2 overexpression in the vasculature may prevent the
development of atherosclerosis in patients with increased
ROS, such as in diabetes, obesity or hypertension [11] and
ameliorate hyperglycemia-induced endothelial dysfunction
[12]. Furthermore, UCP-2 might be playing an important
role in the regulation of energy expenditure and are likely
to contribute to obesity and type 2 diabetes mellitus
(T2DM). In this regard, several UCP-2 gene polymorphisms
were linked to an increased body weight index or obesity in
Pima Indians [13,14] and in Balinese population [15] or
with insulin resistance or T2DM [16–18]. Thus, reduced
UCP gene expression has been found in adipose tissue of
obese subjects and in the first-degree relatives of
T2DM patients. On the other hand, both obese and
diabetic patients have associated vascular complications
such as atherosclerosis [19,20], insulin resistance with
hyperinsulinemia and elevated circulating TNF-α levels
[21]. To get a new insight on that UCP-2 protective effect
on the vasculature, we have studied new molecular
mechanisms that help to explain whether the moderate
hyperinsulinemia or reduction TNF-α levels might have a
protective role against vascular damage mediated by
UCP-2 modulation. Firstly, we have analyzed the effect of
insulin and/or TNF-α on UCP-2 levels in endothelial
and vascular smooth muscle cells. After that, we wondered
if some mechanisms studied in vitro could be of any rele-
vance in vivo. We used the following experimental models:
ApoE−/− mice at 8, 12, 18 or 24 weeks of age, BATIRKO
mice under high-fat diet for 16 weeks and 52-wk-oldBATIRKO mice with o without anti-TNF-α treatment to
address the relationship between UCP-2 expression, or
lipid accumulation, or vascular damage, or oxidative stress,
or insulin or TNF- α plasma levels. Finally, we searched




Primary vascular smooth muscle cells (VSMC) were
obtained from thoracic aorta arteries, immortalized
and cultured as described previously [22]. Endothelial
cell line, SVEC4-10EE2 (clone 2167) was purchased from
ATCC and was cultured in DMEM medium supplemented
with 10% of horse bovine serum, respectively. Both cell
lines were growth-arrested by incubation in medium
without serum for 5 h, and then incubated with the
corresponding stimuli. For experiments in vitro, we
have used TNF-α (10 ng/mL), insulin (10 nmol/L), oleate
(1 mmol/L) and L-NAME (1 mmol/L).
Experimental models
Male mice were maintained in the Animal Care Facility
under the standard conditions of temperature and 12 h
light/dark cycle. All animals from three experimental
models used are under C57BL/6 genetic background.
Male ApoE−/− knockout mice and their control mice
were fed a Western type diet (A04 + 21% kcal from fat)
at six week-age for 2, 6, 12 or 18 weeks respectively.
Male BATIRKO mice [22] were fed on high-fat diet
(A04 + 61% kcal from fat) for 16 weeks or standard diet
(3% calories from fat, A04) for 52 weeks. Moreover, one
group of 52-wk-old BATIRKO mice were treated with
LEAF purified anti-TNF-α (MP6-XT22, Bio-Legend, San
Diego, CA) (50 μg/mouse ip.) every 3 days for 6 weeks
as previously described [23]. All animal experimentation
described in this manuscript was conducted according with
accepted standards of human animal care, as approved
by the corresponding institutional committee. The
investigation also conforms to the Guide for the Care and
Use of Laboratory Animals published by the National
Institutes of Health (NIH Publication No. 85–23, revised
1996) and in accordance with The ARRIVE Guideline for
Reporting Animal research [24].
Western blot
Western blot analyses were performed on protein extracts
from VSMCs, ECs or aorta artery as previously described
[25]. The antibodies used were anti-phospho-AKT (T308),
AKT, p-p70S6K (T389), p70S6K, p-p44/42 (S202/
T204) and p44/42 from Cell Signalling, anti-UCP-2 was
from Calbiochem and anti-β-actin or α-tubulin was from
Sigma-Aldrich Corp.
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Total RNA was extracted from ECs, VSMCs or aorta
artery from mice by TRIzol method (Invitrogen, Carlsbad,
CA). The gene expression was analyzed by real-time
quantitative PCR (qRT-PCR) as described [25].
Analytical procedures
Plasma levels of insulin and TNF-α were analyzed using
ELISA kits (Millipore and SABioSciences, Frederick,
MD, respectively).
Histological analysis
Aortic roots were OCT-embedded and sections of 7 μm
interval were Oil-Red-O/hematoxylin stained was done
to measure lipid depot. The lesion size on aortic root
was also measured as described [22]. Macrophages and
nitrotyrosine levels were detected by immunoperoxidase
with rat anti-mouse F4/80 antigen (MCA497GA, AbD
serotec) and rabbit anti-nitrotyrosine polyclonal Ab
(06–284, Upstate), respectively.
Statistical analysis
All values were expressed as means +/−sem. Data were
analyzed using a one-way analysis of variance, followed
by a Bonferroni test if differences were noted (SPSS 15.0
program). Spearman’s correlation coefficient analysis was
used to assess associations between several parameters
of experimental model. The null hypothesis was rejected
when the p value was less than 0.05.
Results
Differential effect of TNF-alpha and Insulin on UCP-2
expression in vascular cells
Although it is well-known the protective role of UCP-2
against vascular damage [10], the relationship between
insulin or TNF-α with UCP-2 in vascular cells is completely
unknown. Thus, we addressed that issue in ECs and
VSMCs as two major components of the vascular wall.
Firstly, we observed that insulin significantly increased
UCP-2 protein levels at 4, 8 and 18 h in ECs and at 1 h
through 24 h in VSMCs (Figure 1A). We ascertained that
the pre-treatment with 10 ng/mL TNF-α for 2 hours
induced insulin resistance in both vascular cells as shown
by the significant decreases in the phosphorylation of Akt,
p70S6K and p44/42 in cells stimulated with 10 nmol/L
insulin for 10 minutes (Figure 1B). Based on these data, we
analyzed the effect of TNF-α on UCP-2 protein levels.
Thus, 10 ng/mL TNF-α for 2 hours downregulated UCP-2
protein levels in both vascular cells respectively (Figure 1C
and E). More importantly, we also demonstrated that TNF-
α pre-treatment induced a significant decrease of UCP-2
protein levels in VSMCs and ECs stimulated upon insulin
action for 4 h or 18 h, respectively (Figure 1C). At this
stage, we compared insulin effect with a well-knowninductor of UCP-2 expression such as oleate [26]. Firstly,
we observed a significant increase in UCP-2 expression at
mRNA or protein level at 18 h upon oleate treatment in
both vascular cell lines respectively (Figure 1D and E).
However, TNF-α pre-treatment did not significantly impair
UCP-2 protein induced by oleate in both vascular
cells respectively (Figure 1E).
Protective role of UCP-2 against lipid accumulation and
vascular damage
At this step, we wondered if some mechanisms described
in vitro could be of any relevance in vivo. Thus, we
explored in vivo the associations between UCP-2 levels and
lipid accumulation, or vascular damage, or oxidative stress,
or TNF-α levels in the aortic wall, or with circulating
insulin levels. We used different mouse models of
disease. The first one was ApoE−/− mice and their
controls at 8, 12, 18 and 24 wk of age. By Oil-Red-O/
hematoxylin staining, we observed that ApoE−/− mice
developed progressively higher lesion area with higher
lipid content within aortic roots (Figure 2A). We also
analyzed by qRT-PCR UCP-2 mRNA expression and its
likely relationship with the lesion area or lipid content.
Thus, UCP-2 levels augmented significantly within the
aorta from 8 week-old ApoE−/− mice as compared with
their corresponding controls (Figure 2B). However, UCP-2
levels sharply decreased from 12- through 24-wk-old
ApoE−/− mice (Figure 2B). Thus, we established a negative
and significant correlationship between UCP-2 levels and
lesion area or lipid depot within the aortic wall (Figure 2C).
Additionally, we checked that UCP-2 protein levels were
also decreased in 24-wk-old ApoE−/− mice in relation to
theirs controls (Additional file 1: Figure S1A).
The second mouse-model studied was BATIRKO
mice under HFD for 16 weeks. These mice lacking IR
in BAT-specific manner under STD showed severe
brown lipoatrophy, susceptibility to the obesity (mainly in
gonadal WAT compartment), glucose intolerance and a
defect in insulin secretion [22,27]. Moreover, BATIRKO
mice under HFD also showed insulin resistance and more
severe glucose intolerance. So, we have phenotypically
established two groups of obese BATIRKO mice as
characterized by their plasma insulin levels, pancreatic
islet area, islet insulin content, and also by their glucose
tolerance curves and fasting hyperglycemia. The first
group showed compensated insulin resistance (moderately
hyperinsulinemic, BATIRKO MH, fasted insulin plasma
levels = 1.4 ± 0.2 ng/mL, p < 0.05 vs. control group),
marked pancreatic beta cell hyperplasia (0.06 ± 0.01
islet area/pancreas area, p < 0.05 vs. control group)
and higher islet insulin content (0.28 ± 0.02 positive
staining/ islet area, p < 0.05 vs. control group). A second
group showed non-compensated insulin resistance
(normoinsulinemic, BATIRKO N, fasted insulin plasma
Figure 1 Effect of insulin, oleate and TNF-α on UCP-2 expression level in vascular cells. (A) The effect of insulin on UCP-2 expression levels
in ECs and VSMCs was analyzed by Western blot. (B) Effect of TNF-α on the phosphorylation of Akt, p44/42 and p70S6K in both vascular cell lines
stimulated by insulin. (C) Effect of TNF-α pretreatment on UCP-2 protein levels in vascular cell lines stimulated by insulin. (D) qRT-PCR analysis of
UCP-2 mRNA expression in vascular cell lines stimulated by oleate. (E) Effect of TNF-α pretreatment on UCP-2 expression in vascular cell lines
stimulated by oleate. β-Actin was used as loading control. *p < 0.05 vs. control; † p < 0.05 vs. stimulus.
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normal islet size (0.02 ± 0.008 islet area/pancreas area,
ns. vs. control group) and lower islet insulin content
(0.14 ± 0.01 positive staining/islet area, p < 0.05 vs. control
group). In addition, normoinsulinemic obese BATIRKO
mice (N) showed a more severe glucose intolerance and
mild fasting hyperglycemia as compared with moderate
hyperinsulinemic obese BATIRKO mice (MH) (Fasting
glycemia from BATIRKO N= 138 ± 9 mg/dL, p < 0.05 vs.
control group; fasting glycemia from BATIRKO MH=
123 ± 8 mg/dL and from control group = 111 ± 4 mg/dL).
Under this scenario, we observed that BATIRKO MH
mice showed a significant increase of UCP-2 levels as
compared with control or BATIRKO N mice respectively
(Figure 3A and Additional file 1: Figure S1B). At this stage,
we explored the relationship between UCP-2 levels
within the aortic wall and the vascular damage. Thus,
normoinsulinemic obese BATIRKO mice with lower
UCP-2 levels in the aorta showed endothelial dysfunction(Additional file 2: Figure S2A), higher vasoconstrictor
response to angiotensin II or TXA2 (Additional file 2:
Figure S2B), higher lipid depots (Figure 3B), higher
lesion area and macrophage infiltration in aortic roots
(Additional file 2: Figure S2C) as compared with moderate
hyperinsulinemic BATIRKO mice. Moreover, we also
observed a significant negative correlationship between
UCP-2 levels and lipid depots or lesion area in the aorta
in those animals (Figure 3B).
Relationship between TNF-α and UCP-2 expression levels
in vivo
As we had demonstrated in vitro that TNF-α might
downregulate UCP-2 protein levels in vascular cells,
we explored that mechanism in both groups of obese
BATIRKO mice in the aorta (Figure 3C). Normoinsuline-
mic obese BATIRKO mice (N) with lower UCP-2 levels in
aorta and higher vascular damage showed a significant
increase in TNF-α plasma levels, or expressed in WAT or
Figure 2 Role of UCP-2 in the aorta from Control and ApoE−/−mice. (A) Representative photomicrographs of OilredO staining of aortic roots
and quantification of lesion area and lipid content from Control and ApoE−/− mice at 8, 12, 18 or 24 weeks of age. (B) qRT-PCR analysis of UCP-2
mRNA expression in aorta artery. (C) Spearman correlation between UCP-2 expression levels in the aorta by qRT-PCR and lesion area or lipid depot. Control
at 8 weeks (Control 8wk, n = 3); ApoE−/− at 8 weeks (ApoE−/− 8wk, n = 3); Control at 12 weeks (Control 12wk, n = 5); ApoE−/− at 12 weeks (Control 12wk,
n = 4); Control at 18 weeks (Control 18wk, n = 4); ApoE−/− at 18 weeks (ApoE−/− 18wk, n = 6); Control at 24 weeks (Control 24wk, n = 5); ApoE−/− at 24 weeks
(ApoE−/− 24wk, n = 5). *p < 0.05 vs. each control; †p< 0.05 vs. ApoE−/− 8wk; §p < 0.05 vs. ApoE−/− 12wk; #p < 0.05 vs. ApoE−/− 18wk.
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BATIRKO mice (MH) (Figure 3C). Thus, we observed a
significant negative correlationship between UCP-2 and
TNF-α levels in the aorta (Figure 3D). We also explored
those levels in 52-week-old BATIRKO mice under
standard diet. Those mice showed severe brown lipoatro-
phy, obesity, hypoinsulinemia, mild fasting hyperglycemia,
glucose intolerance, vascular dysfunction, macrophage
infiltration, oxidative stress, and a significant increase of
gene markers of endothelial activation and inflammation as
previously characterized [23], TNF-α playing a major role
[23]. Now, we have observed that 52- week-old BATIRKO
mice show a significant reduction of UCP-2 expression
levels, that UCP-2 lowering in the aorta was precluded by
the pre-treatment with anti-TNF-α (Figure 4A and
Additional file 1: Figure S1C and D). In addition, a signifi-
cantly negative correlationship between UCP-2 and TNF-α
expression levels in the aorta was also observed (Figure 4B).Effect of insulin on UCP-2 expression levels in vivo
At this step, we wondered if UCP-2 overexpression
induced by insulin in vitro could be of any relevance
in vivo. For this purpose, we observed that obese
BATIRKO mice with moderate hyperinsulinemia had
higher UCP-2 levels in aorta and lesser vascular dam-
age than normoinsulinemic obese BATIRKO mice
(Figure 3A, B and E and Additional file 1: Figure S1B).
Moreover, we established a positive and significant correl-
ation between circulating insulin levels and UCP-2 levels in
aorta (Figure 3F). In the third experimental model, we also
observed this correlationship between insulin and UCP-2
expression levels (Figure 4C). Thus, 52-week-old control
group displaying moderate hyperinsulinemia showed a
significant increase in UCP-2 expression levels in the aorta
(Figure 3A and Additional file 1: Figure S1D). However,
52-week-old BATIRKO mice showing a lower insulinemia
manifested a significant reduction of UCP-2 expression
Figure 3 Role of UCP-2 in the aorta from Control and BATIRKO mice under high-fat diet. (A) qRT-PCR analysis of UCP-2 expression levels in
aorta from Control and BATIRKO mice under HFD. (B) Representative photomicrographs of OilredO staining of aortic roots from Control and
BATIRKO under high-fat diet and quantification of lipid content and its correlation with UCP-2 expression levels in the aorta. (C) Determination of
TNF-α plasma levels (by ELISA) and in WAT and aorta (by qRT-PCR). (D) Spearman correlation between UCP-2 and TNF-α levels in the aorta by
qRT-PCR. (E) Plasma insulin levels by ELISA in Control and BATIRKO under high-fat diet. (F) Spearman correlation between UCP-2 expression levels
in aorta and plasma insulin levels. Control under HFD (Control; n = 12); moderate hyperinsulinemic obese BATIRKO mice (BATIRKO MH, n = 6); nor-
moinsulinemic obese BATIRKO mice (BATIRKO N, n = 10). *p < 0.05 vs. Control; †p < 0.05 vs. BATIRKO MH mice.
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Additional file 1: Figure S1C and D). On the other
hand, UCP-2 might modify atherosclerotic process
due to the fact that elevated levels of this protein
reduce ROS levels [11]. Thus, we observed a significant
decrease of superoxide anion and nitrotyrosine levels
in aortic roots from moderate hyperinsulinemic as
compared with normoinsulinemic obese BATIRKO mice
(Additional file 2: Figure S2C).
Role of iNOS in the UCP-2 downregulation induced by
TNF-α
Back to in vitro studies, we explored whether the reduc-
tion in UCP-2 levels in the aorta induced by TNF-α
might be mediated at least in part by iNOS in vascular
cells. Thus, we observed by qRT-PCR that TNF-α
treatment for 2, 4 and 8 hours induced a significantrobust increase of iNOS mRNA expression in vascular
cells (Figure 5A). Next step, we observed that the
pre-treatment with iNOS inhibitor (L-NAME) impaired
that rising of the UCP-2 expression levels in ECs or
VSMCs in response to TNF-α (Figure 5B). These data
strongly suggest that TNF-α downregulates UCP-2
expression levels through iNOS expression in the aortic
wall. We explored that relationship between iNOS and
UCP-2 in vivo. Thus, we observed that 18-week-old and
mainly 24-week-old ApoE−/− mice showed a significant
increase of iNOS expression levels together with a signifi-
cant reduction of UCP-2 levels in the aorta (Figure 5C).
Moreover, normoinsulinemic obese BATIRKO mice with
lower UCP-2 levels and higher vascular damage showed a
significant increase of iNOS levels as compared with
moderate hyperinsulinemic BATIRKO mice in the
aorta (Figure 5D).
Figure 4 Effect of anti-TNF-α pre-treatment on UCP-2 expression level in BATIRKO mice. (A) qRT-PCR analysis of UCP-2 mRNA expression
in aorta from Control and BATIRKO mice and anti-TNF-α treated BATIRKO mice at 52 weeks of age. Spearman correlation between UCP-2 expression
levels and TNF-α in the aorta (B), or with plasma insulin levels (C). Control 33 weeks (n = 12); Control 52 weeks (n = 12); BATIRKO 52 weeks (n = 8);
BATIRKO 52 weeks + anti-TNF-α (n = 3). *p < 0.05 vs. Control; †p < 0.05 vs. 52-wk-old-BATIRKO mice.
Figure 5 Role of iNOS in the inhibition of UCP-2 expression level induced by TNF-α. (A) qRT-PCR analysis of iNOS mRNA expression in ECs
and VSMCs stimulated with TNF-α for 2, 4 and 8 hours. (B) Western blot analysis of UCP-2 levels with or without iNOS inhibitor (L-NAME) in ECs
and VSMCs stimulated with TNF-α. *p < 0.05 vs. control; †p < 0.05 vs. stimuli. qRT-PCR analysis of iNOS mRNA expression in aorta from Control and
ApoE−/− mice at 8, 12, 18 and 24 wk of age (C) and Control and BATIRKO mice under high-fat diet (D). *p < 0.05 vs. Control; †p < 0.05 vs. BATIRKO
MH mice.
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Protector role of UCP-2 against lipid depot and vascular
damage
Atherosclerosis is a multi-factorial chronic vascular
inflammatory disease characterized by endothelial dysfunc-
tion and accumulation of lipids, inflammatory cells, smooth
muscle cells and extracellular matrix in the arterial
neointima [28]. Several studies suggest that ROS are
involved in plaque formation [29] and all plaque cellular
components may respond to and be damaged by ROS,
contribute to plaque progression and finally, to plaque
rupture [30]. Thus, several approaches to stop ROS
production and to alter disease progression have been
used [31,32]. In addition, it has been previously published
that UCP-2 overexpression in macrophages decreases
intracellular ROS levels and reduces their immune activity
[33,34]. Moreover, UCP-2 might function as an adaptive
antioxidant defense to protect against the development of
atherosclerosis in response to high fat and cholesterol
diet [35] and improve hyperglycemia-induced endothelial
dysfunction [12]. Under this scenario, our results
demonstrate that high-fat diet BATIRKO mice showing
lower UCP-2 expression levels manifested higher oxidative
stress in the aorta. Moreover, the decrease in UCP-2 levels
in the aorta is strongly inversely correlated with lipid
accumulation and lesion area from 24-week-old ApoE−/−
mice or normoinsulinemic BATIRKO mice in the aorta.
Previous results have also suggested a protective role of
UCP-2 against atherosclerosis [10] showing an antiathero-
genic effect in macrophages, ECs and VSMCs [11].
Thus, UCP-2 higher expression reduced proliferation,
migration and plasminogen activator 1 expression in
human VSMCs [36].
Insulin induces UCP-2 overexpression in aorta protecting
against vascular damage
A better knowledge of UCP-2 expression levels regulation
in the vasculature may improve the management of the
atherosclerotic process. Thus, we explored the association
between insulin and UCP-2 in vivo and in vitro. Our
results suggest that insulin or moderate hyperinsulinemia
in response to insulin resistance induces UCP-2 expression
in ECs and VSMCs or in the aorta from BATIRKO
MH mice respectively. On this regard, we previously
demonstrated that insulin or IGF-1 induce UCP-1 expres-
sion through IRS-1 or AP-1 activity in a PI3K/Akt
dependent manner [37,38]. Others authors had also
described similar effects of insulin on UCP-2 expression
levels in bovine retinal microvascular endothelial cells [39]
or in skeletal muscle [40]. Moreover, it have been described
that intensive insulin therapy suppressed iNOS gene
expression in liver and skeletal muscle, possibly in part via
reduced NF-κB activation, and lowered the elevated circu-
lating NO levels [41]. So, insulin might also reduced NF-κBactivation and iNOS levels in aorta and in consequence
favours UCP-2 overexpression and protect against
vascular damage.
TNF-α downregulates UCP-2 in aorta accelerating vascular
damage
Among several proinflammatory and proatherogenic
signals working on the vasculature TNF-α is relevant the
most. Thus, the relationship between TNF-α and UCP-2
expression levels appears to be of importance in assessing
vascular damage risk. On this regard, we have shown that
insulin and TNF-α have antagonistic effect on UCP-2
expression in ECs and VSMCs. It has been previously
published that proinflammatory cytokines such as TNF-α
and/or IL-1β downregulated UCP-2 levels in adipocytes
[42], INS-1 cells or rat pancreatic islets [43]. Moreover, our
data provide a strong support in vivo to the negative rela-
tionship between TNF-α and UCP-2. Thus, 52-week-old
BATIRKO mice or normoinsulinemic BATIRKO mice
under high-fat diet with lower UCP-2 levels showed
elevated TNF-α expression levels in WAT, plasma and
aorta. Moreover, TNF-α may directly downregulates
adiponectin [44] contributing to the development of
vascular insulin resistance and the decrease of UCP-2
levels in the aorta. On this regard, it has previously been
described that adiponectin induces UCP-2 expression in
the liver [45]. In the two populations of BATIRKO mice,
we observed a negative correlation between TNF-α and
adiponectin levels in both WAT and plasma. Therefore,
higher levels of adiponectin might induce UCP-2 overex-
pression in the aorta attenuating vascular damage. The
use of the anti-TNF-α antibody pre-treatment support the
concept that TNF-α downregulates UCP-2 expression
levels as shown in 52-week-old BATIRKO mice.
Other mechanism involved in the inhibitory effect of
TNF-α on UCP-2 expression levels is the NO-dependent
pathway induction of iNOS expression in ECs and VSMCs
as previously described in 3T3F442A preadipocytes [42].
In vivo, we also demonstrated that anti-TNF-α treatment
in 52-week-old BATIRKO mice is able to reduce NF-κB
activation in white and brown adipose tissues and aorta,
reducing iNOS levels in aorta [24] and increasing UCP-2
levels in aorta and as result lowering vascular damage.
Moreover, LPS promoted the expression of iNOS and
ROS production as well as inflammatory cytokines in
UCP-2−/− macrophages [46,47]. Our data strongly suggest
an inverse correlationship between iNOS and UCP-2. Thus,
24-week-old ApoE−/− mice, normoinsulinemic BATIRKO
mice under high-fat diet and 52-week-old BATIRKO mice
with lower UCP-2 levels had higher iNOS levels and
higher vascular damage. In addition, anti-TNF-α antibody
pre-treatment reduced iNOS expression, restoring UCP-2
levels, and improving vascular alterations from 52-week-old
BATIRKO mice [24].
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In conclusion, our results suggest that insulin and
TNF-α share an antagonistic effect on UCP-2 expression
levels in vascular cells and also in the aorta in vivo.
Thus, moderate hyperinsulinemia in response to insulin
resistance or lowering of TNF-α levels within the aorta
attenuates vascular damage, this protective effect being
mediated by UCP-2 expression levels through iNOS.
Additional files
Additional file 1: Figure S1. UCP-2 protein expression in vivo. UCP-2
protein levels were detected by Western blot and α-tubulin was used as
loading control. UCP-2 protein levels in aorta artery from Control and
ApoE-/- mice at 24 weeks of age (A), Control, moderate hyperinsulinemic
obese BATIRKO and normoinsulinemic obese BATIRKO under HFD (B),
Control at 33 weeks of age, Control and BATIRKO and 52 weeks of age
(C) and anti-TNF-α treated BATIRKO mice at 52 weeks of age (D). (A)
Control at 24 weeks of age (C24; n=3); ApoE-/- mice at 24 weeks of age
(ApoE-/-24, n=3); *p<0.05 vs. C24. (B) Control under HFD (C; n=3); moderate
hyperinsulinemic obese BATIRKO mice (BMH, n=3); normoinsulinemic obese
BATIRKO mice (BN, n=3). †p<0.05 vs. BMH mice. (C and D) Control 33 weeks
(C33, n=3); Control 52 weeks (C52, n=6); BATIRKO 52 weeks (B52w, n=5);
BATIRKO 52 weeks + anti-TNF-α (B52+anti-TNF-α, n=3). †p<0.05 vs. C52;
#p<0.05 vs. B52.
Additional file 2: Figure S2. Characterization of vascular damage in
BATIRKO mice under high-fat diet. (A) Vascular function was studied in
aortic rings from control and BATIRKO mice under HFD. We evaluated
endothelium-dependent relaxations to acetylcholine (Ach; 10-5 mol/L) and
endothelium-independent relaxations induced by sodium nitroprusside
(SNP; 10-7 mol/L) in phenylephrine (10-6 mol/L) precontracted rings. (B)
Contractile responses to thromboxane A2 analogue (U46619; 10-6 mol/L)
and Angiotensin II (Ang II, 10-6 mol/L) in aortic rings from controls and
BATIRKO mice. (C) (Left) Representative photomicrographs of macrophages
immunohistochemistry (F4/80) (first file of panels), of nitrotyrosine levels by
immunohistochemistry (IHC) (second file of panels) and of superoxide anion
levels in situ by hydroethidine method (third file of panels) in aortic roots
from control and BATIRKO mice. (Right) Quantitative analysis of lesion area,
macrophage infiltration, superoxide levels and of nitrotyrosine expression in
aortic roots from control and BATIRKO mice. Results are expressed as mean
± SEM. Control (n=12), BATIRKO MH (n=6), BATIRKO N (n=10). *p<0.05 vs.
Control; †p<0.05 vs. BATIRKO MH mice.
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